Health Care · Pharmaceutical Preparations · Nasdaq · CIK 1419041 · FYE Dec 31 · Prices AT CLOSE 2026-07-30 (USD) — end-of-day, never a live or intraday quote
Last $76.98Day +0.59%Mkt cap $1.1B1Y +655.8%Off 52W high −0.3%Vol (1Y) 131.4%
Daily closing price, split-adjusted to the current basis; 3y shown of 1,363 bars on file. Sampled to 240 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest14.8% of sh out |
| Days to cover1.7d |
| 13F net flow (QoQ)+4.53% |
| Top-10 13F concentration72.3% |
| Next report (est.)2026-10-02 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$75.9M |
| ROE−122.3% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD+182.3% |
| 1Y+655.8% |
| 3Y+204.9% |
| 5Y−89.7% |
| Since incept. (ann.)−34.3% |
Total return through 2026-07-30 · series begins 2021-02-22. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)131.4% |
| Ann. volatility (3Y)136.0% |
| Sharpe (1Y)2.08 |
| Sharpe (3Y)0.83 |
| Max drawdown (1Y)−55.9% |
| Max drawdown (3Y)−83.6% |
| Beta (3Y vs SPY)3.77 |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| FEDERATED HERMES, INC. | 1.8M | $46M | 12.71% | +0.0% |
| FRED ALGER MANAGEMENT, LLC | 1.3M | $33M | 9.17% | −12.8% |
| ORBIMED ADVISORS LLC | 1.2M | $31M | 8.62% | +0.0% |
| JANUS HENDERSON GROUP PLC | 1.2M | $31M | 8.56% | −16.7% |
| Affinity Asset Advisors, LLC | 1.0M | $26M | 7.29% | +2.3% |
| MPM BIOIMPACT LLC | 1.0M | $26M | 7.21% | new |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 950,000 | $25M | 6.84% | +185.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 531,692 | $14M | 3.83% | new |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-04-01 | −$1.24 | — | — | — |
| 2025-09-30 | 2025-11-14 | −$0.99 | — | — | — |
| 2025-06-30 | 2025-08-14 | −$0.96 | — | — | — |
| 2025-03-31 | 2025-05-15 | −$1.37 | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-10-02 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
